124 related articles for article (PubMed ID: 10161507)
1. Antiemetic therapy in managed care oncology: roundtable discussion.
Gerbino PP; Goldsmith M; Kenney JT; Lindley C; Nolte J; Quan W; Reich PR
Med Interface; 1996 Sep; Suppl C():16-35. PubMed ID: 10161507
[TBL] [Abstract][Full Text] [Related]
2. Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish cancer patients: a comparison of efficacy, side-effect profile, and cost.
Abali H; Celik I
Cancer Invest; 2007; 25(3):135-9. PubMed ID: 17530482
[TBL] [Abstract][Full Text] [Related]
3. [Chemotherapy-induced emesis and serotonin antagonists].
Jantunen I; Johansson R
Duodecim; 1991; 107(14):1112-5. PubMed ID: 1670506
[No Abstract] [Full Text] [Related]
4. Impact of ondansetron and granisetron on chemotherapy-induced emesis in adults: the need for comparative pharmacoeconomic data.
Hedayati S; Moatti JP; Seitz JF
Clin Ther; 1994; 16(3):569-80. PubMed ID: 7923321
[TBL] [Abstract][Full Text] [Related]
5. Always more "setrons": how many do we need?
Aapro MS
Support Care Cancer; 1997 Jan; 5(1):1-2. PubMed ID: 9010981
[No Abstract] [Full Text] [Related]
6. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Slabý J; Trnený M; Procházka B; Klener P
Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
[TBL] [Abstract][Full Text] [Related]
7. Oral 5-HT3-receptor antagonists: expanding the options for Medicare outpatients.
Dempsey CL; Shillington AC; Goliak M
J Am Pharm Assoc (Wash); 1998; 38(5):515-6. PubMed ID: 9782682
[No Abstract] [Full Text] [Related]
8. Review of experience with ondansetron and granisetron.
Aapro MS
Ann Oncol; 1993; 4 Suppl 3():9-14. PubMed ID: 8395875
[TBL] [Abstract][Full Text] [Related]
9. 2005 Medicare payments for chemotherapy will exceed costs.
Zielinski SL
J Natl Cancer Inst; 2005 Jan; 97(1):7. PubMed ID: 15632370
[No Abstract] [Full Text] [Related]
10. Effectiveness of oral 5-HT3 receptor antagonists for emetogenic chemotherapy.
Anastasia PJ
Oncol Nurs Forum; 2000 Apr; 27(3):483-93. PubMed ID: 10785902
[TBL] [Abstract][Full Text] [Related]
11. Randomised double blind crossover study comparing ondansetron, granisetron and tropisetron. A cost-benefit analysis.
Barrajon E; de las Peñas R
Support Care Cancer; 2000 Jul; 8(4):323-33. PubMed ID: 10923774
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy.
Jones E; Koyama T; Ho RH; Kuttesch J; Shankar S; Whitlock JA; Cartwright J; Frangoul H
Pediatr Blood Cancer; 2007 Mar; 48(3):330-2. PubMed ID: 16304666
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
14. Granisetron: an update on its clinical use in the management of nausea and vomiting.
Aapro M
Oncologist; 2004; 9(6):673-86. PubMed ID: 15561811
[TBL] [Abstract][Full Text] [Related]
15. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
[TBL] [Abstract][Full Text] [Related]
16. The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis.
Jones AL; Lee GJ; Bosanquet N
Eur J Cancer; 1992; 29A(1):51-6. PubMed ID: 1332738
[TBL] [Abstract][Full Text] [Related]
17. Management of vomiting associated with cytotoxic therapy.
Jones AL; Cunningham D
Br J Hosp Med; 1991 Feb; 45(2):85-8. PubMed ID: 2018889
[TBL] [Abstract][Full Text] [Related]
18. Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens.
Trigg ME; Inverso DM
Bone Marrow Transplant; 2008 Oct; 42(8):501-6. PubMed ID: 18724391
[TBL] [Abstract][Full Text] [Related]
19. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation.
Fox-Geiman MP; Fisher SG; Kiley K; Fletcher-Gonzalez D; Porter N; Stiff P
Biol Blood Marrow Transplant; 2001; 7(11):596-603. PubMed ID: 11760147
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy.
Kwong WJ; Parasuraman TV
Pharm Pract Manag Q; 1999 Apr; 19(1):28-41. PubMed ID: 10351607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
